NYSNSATTR

ATTRv-PN: Advances in Understanding and Managing Amyloid Disease with Peripheral Neuropathy

Thursday, March 27th from 6:00pm - 7:00pm ET

Name:

First NameLast Name

Credentials:

State Licensed to Practice in:

Email:

example@example.com

1. Transthyretin is the protein that misfolds causing hereditary amyloidosis. It is produced in which of the following organs?

2. Amyloid polyneuropathy is most often confused with:

3. The NEURO-TTRansform study revealed that hATTR-PN patients treated with eplontersen reduced serum TTR by 81%. The root of administration for this novel therapy is:

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Review the accurate and timely diagnosis of ATTRv-PN based on clinical suspicion and guidelines-directed testing strategies.
Understand the pathophysiology of ATTR disease and the mechanistic rationale for new and emerging therapies.
Develop individualized treatment plans for ATTRv-PN based on recent clinical data, patient prognosis, a review of treatment options, an assessment of safety, and shared decision making.

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Please rate the faculty on his overall teaching ability:

Rows	Poor	Fair	Good	Very Good	Excellent
Nivedita Jerath, MD

Do you feel this activity was fair balanced and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

What factors beyond clinical care that effect the health of your patients does your team experience?

courseTitle

credit-amount

Overall Activity Feedback